At this symposium, experts share the latest advances in the research of the microbiome and its relationship with NAFLD. They will discuss the microbiome’s association with disease progression, fibrosis and hepatocellular carcinoma. Topics covered will include the “cross talk” between obesity, the microbiome and NAFLD in both animal models and humans.
The microbiome is recognized as an important player in liver disease pathogenesis. The liver’s close proximity to the gut makes it particularly susceptible to changes in the intestinal microbiome. This workshop uses the microbiome as an example to facilitate appreciation of the tools available to perform clinical research, as well as specific research tactics for microbiome-related study.
At this symposium, experts on pediatric acute liver failure (PALF) will review the role of inflammation in etiopathogenesis of common comorbidities and discuss emerging topics in pediatric acute-on-chronic liver failure and extrahepatic support strategies. They will discuss the complexity of medical decision making in PALF and review indications for liver transplant in these patients.
The Career Development Workshop is designed for hepatologists in the early career stage. Participants will explore how to maximize career opportunities in basic and clinical research, and will discuss potential sources of research funding for each pathway. They will also review an array of career pathways in both academic and community practice, and possible rewards and challenges hepatologists may encounter.
Recent advances in liver bio-engineering have led to multiple in vitro culture systems that duplicate many complex cell-cell interactions of the intact liver. This symposium will highlight recent advances in this field, show current use of ex-vivo, 3D multicellular culture systems as probes of liver function and disease and update the progress toward the generation of the bio-artificial liver.
Review steps to develop programs to eradicate HCV in the U.S. at this program. Speakers will address the current state of screening, novel models to engage more patients into therapy and the current state of access to HCV therapeutics, including generics. They will contrast U.S. efforts to eradicate HCV with programs from around the world.
Berangere Gapp, Marie Jourdain, Pauline Bringer, Benjamin Kueng, Delphine Weber, Arnaud Osmont, Stefan Zurbruegg, Judith Knehr, Rocco Falchetto, Guglielmo Roma, William Dietrich, Reginald Valdez, Nicolau Beckmann, Florian Nigsch, Arun J. Sanyal, Iwona Ksiazek – 8 November 2019 – A promising approach for the treatment of nonalcoholic steatohepatitis (NASH) is the inhibition of enhanced hepatic de novo lipogenesis (DNL), which is the synthesis of fatty acids from nonlipid sources.
Brian P. Lee, Eric Vittinghoff, Mark J. Pletcher, Jennifer L. Dodge, Norah A. Terrault – 8 November 2019
Naim Alkhouri, Rohit Kohli, Ariel E. Feldstein – 8 November 2019 – Nonalcoholic fatty liver disease (NAFLD) is common in children and may progress to nonalcoholic steatohepatitis (NASH), advanced fibrosis, and even cirrhosis in childhood or early adulthood, indicating the need for pharmacologic treatment in this age group. Multiple trials are evaluating different therapeutic targets for NASH with fibrosis in adults, and the U.S.
Angela C. Cheung, Douglas I. Walker, Brian D. Juran, Gary W. Miller, Konstantinos N. Lazaridis – 8 November 2019